Zusammenfassung
Sowohl im klinischen Alltag als auch in der Forschung hat die Aufmerksamkeit für ersterkrankte Patienten mit schizophrenen Psychosen zugenommen, da sich diese Patientengruppe von mehrfach erkrankten Patienten in vielen Aspekten unterscheidet. Man geht davon aus, dass sich mit den heute zur Verfügung stehenden Therapieverfahren der weitere Krankheitsverlauf gerade in dieser frühen Phase nachhaltig günstig beeinflussen lässt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aguilar EJ, Keshavan MS, Martinez-Quiles MD, Hernadez J, Gomez-Beneyto M, Schooler NR (1994) Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 151: 1819–1821
American Psychiatric Association (2004) Practice guideline for the treatment of patients with schizophrenia, 2nd edn. American Psychiatric Association, Washington DC
Bottlender R, Sato T, Jäger M, Groll C, Strauss A, Möller HJ (2002) The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. Eur Arch Psychiatry Clin Neurosci 252: 226–231
Coldham EL, Addington J, Addington D (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106: 286–290
Csernansky JG, Mahmoud R, Brenner R (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16–22
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (2006) Behandlungsleitlinie Schizophrenie. Steinkopff, Darmstadt
Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159: 103–108
Emsley R (1999) Risperidone in the treatment of first-episode psychotic patients: a double blind multicenter study. Risperidone Working Group. Schizophr Bull 25: 721–729
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ (2005) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6: 132–191
Geddes J, Freemantle N, Harrison P, Bebbington P (2002) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 32: 1371–1376
Jäger M, Riedel M, Messer T, Pfeiffer H, Laux G, Naber D, Gaebel W, Huff W, Schmidt LG, Heuser I, Buchkremer G, Kühn KU, Lemke MR, Rüther E, Gastpar M, Bottlender R, Strauß A, Möller HJ (2007) Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 257: 47–53
Larsen TK, Friis S, Haahr U, Joa I, Johannessen JO, Melle I, Opjordsmoen S, Simonsen E, Vaglum P (2001) Early detection and intervention in first episode schizophrenia: a critical review. Acta Psychiatr Scand 103: 323–334
Lieberman JA, Alvir J, Woerner M, Degreet G, Bilder RM, Ashtari M, Bogerts B, Mayerhoff DI, Geisler SH, Loebel A, Levy DL, Hinrichsen G, Szymanski S, Chakos M, Koreen A, Borenstein M, Kane J (1992) Prospective study of psychobiology in first episode schizophrenia at Hillside Hospital. Schizophr Bull 18: 351–371
Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir J, Bilder R (1996) Factors influencing treatment response and outcome of first episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 57 [Suppl 9]: 5–9
Lieberman JA (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46: 729–739
Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160: 1396–1404
Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, Mintz J, Liberman RP, Blair KE (2003) Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 160: 1405–1412
McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia. a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48: 739–745
Merlo MC, Hofer H, Gekle W, Berger G, Ventura J, Panhuber I, Latour G, Marder SR (2002) Risperidone, 2 mg/day vs. 4 mg/day, in first episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry 63: 885–891
Möller HJ (2001) Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 1: 75–91
Möller HJ (2003) Management of the negative symptoms of schizophrenia: new treatment options. CNS-Drugs 17: 793–823
Möller HJ (2005) Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci 255: 190–201
Ohlsen RI, O’Toole MS, Purvis RG, Walters JTR, Taylor TM, Jones HM, Pilowsky LS (2004) Clinical effectiveness in first episode patients. Eur Neuropsychopharmacol 14: S445–S451
Sanger TM, Lieberman JA, Tohen M, Grundy A, Beasley C, Tollefson GD (1999) Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 165: 79–87
Zhang-Wong J, Zipursky RB, Beiser M, Bean G (1999) Optimal haloperidol dosage in first-episode psychosis. Can J Psychiatry 44: 164–167
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this paper
Cite this paper
Jäger, M., Möller, HJ. (2010). Therapeutische Effekte von Haloperidol und Risperidon bei schizophrenen Ersterkrankten im Vergleich. In: Möller, HJ., Müller, N. (eds) Schizophrenie — Zukunftsperspektiven in Klinik und Forschung. Springer, Vienna. https://doi.org/10.1007/978-3-211-92215-6_15
Download citation
DOI: https://doi.org/10.1007/978-3-211-92215-6_15
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-92214-9
Online ISBN: 978-3-211-92215-6
eBook Packages: Medicine (German Language)